
CADTH 2016-2017 at a Glance



- 1. Nabilone for Chronic Pain Management
- 2. CDEC Final Recommendation: Asunaprevir
- 3. Economic Evaluation of Health Technologies
- 4. Behavioural Interventions: Preschoolers with Autism
- 5. PRESS Peer Review of Electronic Search Strategies
- 6. Issues in Emerging Health Technology Nuchal Translucency Measurement in First Trimester Down Syndrome Screening
- 7. pERC Final Recommendation: Nivolumab
- 8. Use of Lidocaine on Adults with Open Wounds
- 9. 2014 Horizon Scan Roundup
- 10. CDEC Final Recommendation: Humira

Customer Satisfaction





30 PartnershipsDeveloped with Canadian Organizations



"CADTH staff participated on the committee responsible for developing the Canadian Standards Association (CSA Group) Express Document on hip protectors released in May 2017. They provided leadership in the development of knowledge mobilization tools. These summaries and guidance cards will help allow the important information about the selection, use, and care of a hip protector to be accessed by a wide audience. We thank CADTH for their contributions to this new initiative."

"CADTH has been instrumental to the work we are doing at ISMP Canada with regards to engaging patients in medication safety; for instance, providing us with the support to translate and disseminate '5 questions to ask about your medications' into 3 Indigenous languages (Cree, Ojibwe, Inuktitut) which allowed this message to be shared and accessed by these groups of people. ISMP Canada continues to turn to CADTH's many resources to inform our work to improve patient safety."

Reports Completed 2016-2017

CDR

pCODR

Rapid Response

HTA and Plasma Products

Optimal Use and Therapeutic Reviews Environmental Scans

Horizon Scans

Methods

Website Visits

2015-2016 **483,937**

+27% increase

2016-2017 **615,872**

Number of errata in 2016-2017 out of total reports published from 2012-2013 to 2016-2017

7/1,770

Percentage of administration to total expenditures

11.0% 11.8%

2015-2016

2016-2017

Customer Satisfaction

From the time that a submission is accepted for review, both pCODR and CDR strive to issue an embargoed recommendation within a 180-calendar-day timeline. In 2016-2017, CDR met the performance measures 98% of the time and pCODR 100% of the time.





Alignment with reimbursement recommendations The consistency with what with the consistency with what recommendations.

The consistency with which jurisdictions align their drug plan listing decisions with the reimbursement recommendations of expert committees.





57

Number of Policy & Practice Changes Informed by CADTH Products In a few jurisdictions, CADTH reports on using wireless devices in hospital settings have helped to inform policies outlining how mobile devices can be safely used in a primary care setting. The policies outline how these devices may be used to ensure that they do not interfere with sensitive medical equipment.

The Western Regional Health Authority in Newfoundland and Labrador has integrated the use of CADTH's Rapid Response service as a highly recommended step in the development of the telehealth services offered through Western Health. As a result, CADTH is helping improve the delivery of health care services to clients, patients, and residents within the Health Authority, especially to those living in rural areas.

The CADTH review on buprenorphine/naloxone has been used in several jurisdictions across Canada as part of the evidence used to make changes to the coverage of that drug for federal, provincial, and territorial (F/P/T) drug plans. These changes help facilitate access to buprenorphine/naloxone for individuals covered by F/P/T drug plans, which has been shown effective in treating opioid use disorder.

The Drug Evaluation Unit, Nova Scotia Health Authority, incorporated CADTH chronic obstructive pulmonary disease (COPD) work into the Dalhousie Academic Detailing Service's topic "What to do with all these New Inhalers". This topic, focused on the best evidence for COPD, was shared with 364 clinicians to date across Nova Scotia. The detailing is still underway and will reach over 400 Nova Scotia clinicians before it is complete. There has been great feedback on its usefulness from clinicians.





Tools Developed

ABOUT CADTH

CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system.

 ${\sf CADTH}\ receives\ funding\ from\ Canada's\ federal,\ provincial,\ and\ territorial\ governments,\ with\ the\ exception\ of\ Quebec.$